Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study
28 sept. 2022 09h25 HE
|
Medicenna Therapeutics Corp.
Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in...
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
22 sept. 2022 07h30 HE
|
Medicenna Therapeutics Corp.
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer ...
Medicenna Announces Results of Annual Meeting of Shareholders
21 sept. 2022 17h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
13 sept. 2022 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at Investor and Scientific Conferences in September
08 sept. 2022 07h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today...
Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights
15 août 2022 07h00 HE
|
Medicenna Therapeutics Corp.
-- Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline -- New MDNA11 Data From Dose Escalation in ABILITY Study Shows Tumor Control In...
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline
11 août 2022 10h42 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to...
Medicenna Announces Pricing of US$20 Million Public Offering of Units
09 août 2022 09h15 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today...
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
08 août 2022 16h15 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today...
Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022
05 août 2022 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...